Regulatory Filings • Apr 15, 2015
Regulatory Filings
Open in ViewerOpens in native device viewer
PRESS RELEASE
April 14, 2015 — New Brighton (Minnesota, USA) — Cellectis Plant Sciences, Inc. a Minnesota-based company focusing on developing healthier food products, has announced today that the Plant Biotechnology Journal has accepted the publication of its peer-reviewed manuscript demonstrating the phenotypic validation of potato lines developed by inactivating a single endogenous gene responsible for sugar accumulation when stored at cold temperatures.
The non-transgenic product has already received an approval from the USDA to be grown in fields. The field trial will start this spring to obtain commercial proof of concept of largescale cold storability and reduced acrylamide content for French fries, potato chips and fresh-cut applications.
"We firmly believe that the new product developed by our team opens the path to the future of food products," commented Luc Mathis, Chief Executive Officer of Cellectis Plant Sciences. "Consumers want access to higher quality products developed without using unhealthy chemicals that are currently used to avoid sprouting of potatoes stored at room temperature. The reduction in fried products of the potentially carcinogenic compound acrylamide will bring additional benefits to consumers."
Benjamin M. Clasen, Thomas J. Stoddard, Song Luo, Zachary L. Demorest, Jin Li, Frederic Cedrone, Redeat Tibebu, Shawn Davison, Erin E. Ray, Aurelie Daulhac, Andrew Coffman, Ann Yabandith, Adam Retterath, William Haun, Nicholas J. Baltes, Luc Mathis, Daniel F. Voytas and Feng Zhang Article first published online: April 7, 2015 DOI: 10.1111/pbi.12370
Media contacts Jennifer Moore, Director of Communications Phone: 917-580-1088 email: [email protected]
Brad Miles Phone: 646-513-3125 email: [email protected]
IR contacts Simon Harnest, VP Finance and Investor Relations Phone: 646-385-9008 email: [email protected]
Founded in 2010, Cellectis Plant Sciences is based in New Brighton, Minnesota (United States). The company has developed a platform to improve the quality of crops for the food and agriculture industries. Cellectis Plant Sciences is involved in a network of collaborations that include global companies (Bayer, Limagrain, Monsanto, and SESVanderhave, among others), as well as leading healthcare (Mitsubishi Tanabe Pharma) and food companies. Cellectis Plant Sciences is developing innovative products with prominent partners in order to secure accessibility of its products to consumers.
For further information please visit our website: www.cellectis-plantsciences.com
This press release contains forward-looking statements. You should not place undue reliance on such statements because they are subject to numerous risks and uncertainties relating to the company's operations and business environment, all of which are difficult to predict and many are beyond the company's control. Forward-looking statements include information concerning the company's possible or assumed future results of operations, including descriptions of its business strategy. These statements often include words such as "anticipate," "believe," "can," "could," "estimate," "expect," "intend," "is designed to," "may," "might," "plan," "potential," "predict," "objective," "should," or similar expressions. These factors are more fully discussed in the "Risk Factors" section and elsewhere in the company's Registration Statement on Form F-1, as amended (File No. 333-202205). You should understand that these statements are not guarantees of performance or results. They involve known and unknown risks, uncertainties and assumptions. Although the company believes that these forward-looking statements are based on reasonable assumptions, you should be aware that many factors could affect its actual financial results or results of operations and could cause actual results to differ materially from those in these forward-looking statements. The company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.